Evidence map›Paper›PMID 36817674›Full record

ArticleArchives of medical science : AMS2023

Not as black as it is painted? The impact of the first wave of COVID-19 pandemic on surgical treatment of urological cancer patients in Poland - a cross-country experience.

Piotr Zapała, Aleksander Ślusarczyk, Paweł Rajwa, Mikołaj Przydacz, Wojciech Krajewski, Bartosz Dybowski, Przemysław Kubik, Błażej Kuffel, Maciej Przudzik, Rafał Osiecki and 20 more

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 8 institutions in 1 country.

Piotr ZapałaDepartment of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
Aleksander ŚlusarczykDepartment of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
Paweł RajwaDepartment of Urology, Medical University of Silesia, Katowice, Poland.
Mikołaj PrzydaczDepartment of Urology, Jagiellonian University Medical College, Krakow, Poland.
Wojciech KrajewskiDepartment of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland.
Bartosz DybowskiDepartment of Urology, Roefler Memorial Hospital, Pruszkow, Poland.
Przemysław KubikDepartment of General and Oncologic Urology, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland.
Błażej KuffelDepartment of General and Oncologic Urology, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland.
Maciej PrzudzikDepartment of Urology, Faculty of Medicine, University of Warmia and Mazury, Olsztyn, Poland.
Rafał OsieckiDepartment of Urology, Centre of Postgraduate Medical Education, Professor W. Orłowski Independent Public Teaching Hospital, Warsaw, Poland.
Remigiusz StamirowskiDepartment of Urology and Urooncology, Multispecialty Regional Hospital, Gorzow Wielkopolski, Poland.
Łukasz ZapałaDepartment of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
Mieszko KozikowskiDepartment of Urology, Centre of Postgraduate Medical Education, Professor W. Orłowski Independent Public Teaching Hospital, Warsaw, Poland.
Dominik ChorągwickiDepartment of Urology, Jagiellonian University Medical College, Krakow, Poland.
Magdalena SzymańskaDepartment of General and Oncologic Urology, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland.
Paweł KiełbDepartment of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland.
Bartosz MałkiewiczDepartment of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland.
Jacek ZostawaDepartment of Urology, Medical University of Silesia, Katowice, Poland.
Marek RoslanDepartment of Urology, Faculty of Medicine, University of Warmia and Mazury, Olsztyn, Poland.
Joanna ZajączkowskaDepartment of Urology and Urooncology, Multispecialty Regional Hospital, Gorzow Wielkopolski, Poland.
Marcin JarzemskiDepartment of Urology, Jan Biziel University Hospital, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Bartosz BrzoszczykDepartment of Urology, Jan Biziel University Hospital, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Piotr PetraszDepartment of Urology and Urooncology, Multispecialty Regional Hospital, Gorzow Wielkopolski, Poland.
Piotr JarzemskiDepartment of Urology, Jan Biziel University Hospital, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Romuald ZdrojowyDepartment of Urology and Oncologic Urology, Wroclaw Medical University, Wroclaw, Poland.
Jakub DobruchDepartment of Urology, Centre of Postgraduate Medical Education, Professor W. Orłowski Independent Public Teaching Hospital, Warsaw, Poland.
Andrzej ParadyszDepartment of Urology, Medical University of Silesia, Katowice, Poland.
Tomasz DrewaDepartment of General and Oncologic Urology, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland.
Piotr ChłostaDepartment of Urology, Jagiellonian University Medical College, Krakow, Poland.
Piotr RadziszewskiDepartment of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
Antoni Jurasz University Hospital · PLMedical University of Warsaw · PLWroclaw Medical University · PLJagiellonian University · PLMedical University of Silesia · PLNicolaus Copernicus University · PLWyższa Szkoła Biznesu w Gorzowie Wielkopolskim · PLUniversity of Warmia and Mazury in Olsztyn · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In the majority of Western European countries, the coronavirus disease (COVID-19) pandemic has led to a dramatic reduction in urooncological surgeries. Our objective was to evaluate the impact of the pandemic on volume and patterns of urooncological surgery in Poland. Material and methods: This is a retrospective analysis of 10 urologic centres in Poland. Data regarding major oncological procedures performed after the COVID-19 pandemic outbreak (March 15, 2020 - May 31, 2020) were evaluated and compared with data from the respective period in 2019. Results: Between March 15, 2020 and May 31, 2020, a total of 968 oncological procedures were performed in participating centres. When compared to the respective period in 2019 (1063 procedures) the overall number of surgeries declined by 8.9%. The reduction was observed for transurethral resection of bladder tumour (TURBT) (20.1%) and partial nephrectomies (PN) (16.5%). Surgical activity considering radical nephrectomy (RN), nephroureterectomy (NU), and radical prostatectomy (RP) remained relatively unchanged, whereas radical cystectomy (RC) burden showed a significant increase (90.9%). Characteristics of patients treated with TURBT, RC, NU, PN, and RN did not differ significantly between the compared periods, whereas RP in the COVID-19 period was performed more frequently in patients with a higher grade group ( Conclusions: Surgical activity for urological cancers in Poland has been maintained during the first wave of the COVID-19 pandemic. The Polish strategy in the initial period of the COVID-19 crisis mirrors the scenario of hard initial lockdown followed by adaptive lockdown, during which oncological care remained undisrupted and did not require particular priority triage.

Indexed as

coronavirusCOVID-19SARS-CoV-2urological cancerurooncological surgery

Identifiers

PMID36817674
PMCPMC9897107
OpenAlexW3128139788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.